Viatris biedt mid-cap value exposure aan de wereldwijde generieke en biosimilars markt, met stabiele kasstromen uit zijn breed portfolio van geneesmiddelen zonder patent.
Viatris is een wereldwijd gezondheidszorgbedrijf gevormd uit de Pfizer-Mylan fusie, dat een breed portfolio van generieke geneesmiddelen, merkgeneesmiddelen en biosimilars produceert in diverse therapeutische gebieden.
Viatris, formed from the 2020 merger of Mylan and Pfizer's Upjohn division, is a global pharmaceutical company focused on generic, branded, and biosimilar medicines. The investment thesis centers on its deep value characteristics " the stock trades at a significant discount to peers on P/E and EV/EBITDA metrics, reflecting market skepticism about its growth trajectory. The company has made progress deleveraging its balance sheet through asset divestitures, including selling its biosimilar portfolio and OTC business, using proceeds to reduce debt. Viatris offers an attractive dividend yield, appealing to income-oriented investors. However, the bear case is substantial: the core generics business faces persistent pricing erosion, revenue has been declining organically, and the new product pipeline must consistently deliver to offset base business erosion. Management's pivot toward higher-growth branded products through acquisitions like Oyster Point and Famy Life Sciences signals strategic ambition but introduces execution risk. For patient value investors comfortable with pharmaceutical industry headwinds, Viatris offers a compelling risk-reward at current valuations, though catalysts for re-rating remain uncertain.
Latest from Otrai
A stock index is a single number that summarizes the price action of a basket of companies. The S&P 500 tracks roughly 500 large US firms, the Nasdaq-100 tracks the 100 largest non-financial names on the Nasdaq exchange, and the Dow Jones Industrial Average follows 30 blue-chip stocks.
The Greeks explain why an option costs what it costs and how that price changes when the stock moves, time passes, and volatility shifts. Delta, Gamma, Theta, and Vega, made accessible.
Chart patterns are the most recognizable part of technical analysis and the most misunderstood. Most fail or break out the wrong way before reversing. This guide covers head and shoulders, double tops and bottoms, triangles, and flags — with realistic reliability, target measurement, and false-breakout confirmation.
Elke trader heeft een strategie die in hun hoofd geweldig eruit ziet. Backtesting is hoe je ontdekt of het werkelijk werkt. Hier is hoe je strategieën correct test, welke statistieken belangrijk zijn en waarom de meeste backtestresultaten te mooi om waar te zijn zijn.
Powered by Rexiew